Prostate Cancer Prevention Trial risk calculator for evaluating the risk of prostate cancer in the high-risk Chinese population.
- Author:
Xiao-Dong ZHU
1
;
An ZHENG
1
;
Zhi-Qian WANG
1
;
Qiang SHAO
1
Author Information
1. Department of Urology, Beijing Electric Power Hospital, Capital Medical University, Beijing 100073, China.
- Publication Type:Journal Article
- Keywords:
Prostate Cancer Prevention Trial risk calculator;
evaluation;
prostate biopsy;
prostate-specific antigen;
prostate cancer
- MeSH:
Age Factors;
Aged;
Asian Continental Ancestry Group;
Biopsy;
China;
Continental Population Groups;
Digital Rectal Examination;
Humans;
Male;
Prostate;
pathology;
Prostate-Specific Antigen;
blood;
Prostatic Neoplasms;
blood;
pathology;
prevention & control;
ROC Curve;
Risk Assessment;
methods;
Risk Factors
- From:National Journal of Andrology
2018;24(2):142-146
- CountryChina
- Language:Chinese
-
Abstract:
Objective:The Prostate Cancer Prevention Trial risk calculator (PCPT-RC) is an online tool for assessing the risk of prostate cancer (PCa) based on age, race, serum PSA, biopsy history, family history, and other factors. This study aimed to investigate the value, sensitivity and specificity of the PCPT-RC 2.0 in assessing the risk of PCa in the Chinese high-risk population.
METHODS:This study included 622 patients with the high risk of PCa characterized by high serum PSA (PSA >3 μg/L) or abnormality in digital rectal examination or imaging of the prostate. According to the results of prostate biopsy, we divided the patients into a PCa and a non-PCa group and used the PCPT-RC 2.0 for evaluation of all the cases followed by statistical analysis.
RESULTS:PCa was detected in 264 (42.4%) of the 622 patients, including 126 cases of high-grade malignancy. Compared with the non-PCa group, the PCa patients showed a significantly older age (［68.40 ± 7.30］ vs ［72.80 ± 7.20］ yr, P <0.001), higher serum PSA level (［11.20 ± 7.76］ vs ［15.06 ± 10.65］, P <0.001), and higher PCPT risk score (［37.0 ± 10.8］% vs ［44.4 ± 12.6］%, P <0.001). The PCPT risk score exhibited a greater area under the ROC curve than the level of serum PSA in evaluating the risk of PCa (0.67 vs 0.61, P <0.05), but no statistically significant difference between the two in predicting the risk of high-grade malignancy (0.67 vs 0.66, P >0.05).
CONCLUSIONS:The PCPT risk score is valuable in predicting the risk of PCa in China, which may play a better role than the serum PSA level in screening PCa and avoid unnecessary prostate biopsy, though its advantage is not so obvious in identifying high-grade malignancy. A prediction tool needs to be established for evaluating the risk of PCa in the Chinese population.
